Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.50 |
| ▸ | LTA4H | P09960 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | USP9X | Q93008 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303384 | 0.89 | PTGDR2 (0.40) | PTGDR2HCRTR1HCRTR2P2RX7 | |
| SCHEMBL3303664 | 0.82 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL3302244 | 0.82 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL4440112 | 0.81 | BRD4 (0.33) | PTGDR2LTA4HHCRTR1HCRTR2USP9X | |
| SCHEMBL3299837 | 0.81 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL3567663 | 0.80 | PTGDR2 (0.58) | PTGDR2PTGS2 | |
| SCHEMBL3299818 | 0.79 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL3570130 | 0.78 | PTGDR2 (0.56) | PTGDR2PTGS1PTGS2 | |
| SCHEMBL2770201 | 0.77 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL3300935 | 0.77 | PTGDR2 (0.51) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121686-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | HRH2, HRH4, HRH1 | PTGDR2 168/4885LTA4H 553/4885HCRTR1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.